Compare Sabra Health Care REIT, Inc. (SBRA) vs Ventas, Inc. (VTR) Stock

Ventas, Inc. (VTR) offers the better valuation at 159.6x trailing P/E (114.3x forward), making it the more compelling value choice. Analysts rate Ventas, Inc. (VTR) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Sabra Health Care REIT, Inc. is actually cheaper at 29.3x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Ventas, Inc. (VTR) delivered a total return of +80.6%, compared to +51.2% for Sabra Health Care REIT, Inc. (SBRA). A $10,000 investment in VTR five years ago would be worth approximately $18K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VTR returned +97.3% versus SBRA's +76.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sabra Health Care REIT, Inc. (SBRA) is the lower-risk stock at 0.05β versus Ventas, Inc.'s 0.23β — meaning VTR is approximately 391% more volatile than SBRA relative to the S&P 500. On balance sheet safety, Sabra Health Care REIT, Inc. (SBRA) carries a lower debt/equity ratio of 45% versus 104% for Ventas, Inc. — giving it more financial flexibility in a downturn.

Sabra Health Care REIT, Inc. (SBRA) is the more profitable company, earning 20.0% net margin versus 4.3% for Ventas, Inc. — meaning it keeps 20.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SBRA leads at 25.7% versus 14.2% for VTR. At the gross margin level — before operating expenses — SBRA leads at 48.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sabra Health Care REIT, Inc. (SBRA) trades at 29.3x forward P/E versus 114.3x for Ventas, Inc. — 84.9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SBRA: 3.8% to $21.33.

In this comparison, SBRA (5.8% yield) pays a dividend. VTR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Sabra Health Care REIT, Inc. (SBRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.05), 5.8% yield). Both have compounded well over 10 years (SBRA: +76.5%, VTR: +97.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: SBRA is a small-cap income-oriented stock; VTR is a mid-cap quality compounder stock. SBRA pays a dividend while VTR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.